IOVA vs RLAY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IOVA · Iovance Biotherapeutics$8.04 ▲ 3.88%
RLAY · Relay Therapeutics$18.60 ▲ 9.41%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IOVA +239.2%
- RLAY +201.5%
Head to head
| Metric | IOVA | RLAY |
|---|---|---|
| Price | $8.04 | $18.60 |
| Change today | ▲ 3.88% | ▲ 9.41% |
| Market cap | $3.72B | $4.11B |
| Return, 3 months | +25.6% | -6.7% |
| Return, year to date | +194.5% | +119.9% |
| Return, 1 year | +249.6% | +207.4% |
| P/E (TTM) | – | – |
| P/B | 4.6 | 5.0 |
| P/E percentile vs own 5y | 3rd | 6th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +65.7% | -48.3% |
| Net profit growth (YoY) | +57.6% | -18.9% |
| Gross margin | 48.4% | – |
| Operating margin | -91.1% | -2,999.4% |
| Net margin | -89.1% | -2,763.6% |
| Return on equity | -40.7% | -36.8% |
| Analyst target vs. price | +95.9% | +45.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 33 | 53 |
| 30-day volatility | 172.4% | 62.7% |
| Max drawdown, 1 year | -47.9% | -28.2% |
| Trend read | Leaning bearish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RLAY is the largest of the group by market value.
- IOVA has returned the most over the past year.
- IOVA is growing revenue fastest.
- IOVA keeps the most profit per dollar of sales.
- RLAY has been the calmest stock over the last 30 days.